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Abstract The aim of this work is to explore the efficacy ,
safety, and patients' satisfaction of laparoscopic uterosacral
nerve ablation (LUNA) in relief of pain in women with
chronic pelvic pain in whom diagnostic laparoscopy reveals
either no pathology or mild endometriosis (AFS score ≤5).
The study was a prospective, single-blind, randomized trial
with 12 months follow-up. It was conducted at the
endoscopy unit of the Gynecology Department of El Minia
University Hospital, Egypt. One hundred ninety Egyptian
women consented to participate in the study. These eligible
patients were randomized using computer-generated tables
and were divided into two equal groups, including the
control group (diagnostic laparoscopy with no pelvic
denervation) and the study group (diagnostic laparoscopy
plus LUNA). Diagnostic laparoscopy with or without
laparoscopic uterosacral nerve ablation was done. There
were no statistically significant difference between both
groups regarding the efficacy and the overall success rate
(between group I and group II, it was 77.64%, 76.47%, and
74.11% versus 79.06%, 75.58%, and 73.25% at 3, 6, and
12 months, respectively) and the cumulative patients'
satisfaction rate (it was 74.11%, 74.11%, and 71.76% versus
75.58%, 75.58%, and 72.09% at 3, 6, and 12 months
between group I and group II, respectively; P≤0.05). There
was no statistically significant difference between both
groups as regards the effectiveness of LUNA in the treatment
of primary (spasmodic) and secondary (congestive) dysmen-
orrhea (P≤0.05), while there was a statistically significant
difference between both groups in the treatment of dyspar-
eunia (P≥0.05). LUNA can be a last alternative option in
well-selected patients for control of chronic pelvic pain
without endometriosis; however, its effectiveness may not
extend to other indications. Also, preliminary experience in
the treatment of primary deep dyspareunia presents a
promising perspective on the management of deep dyspar-
eunia, especially if it will involve a team of social,
psychological, and gynecological specialists.
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Background
Chronic pelvic pain (CPP) can be defined as intermittent or
constant pain in the lower abdomen or pelvis of at least
6 months’ duration, not occurring exclusively with men-
struation or intercourse, and not associated with pregnancy;
it is a symptom, not a diagnosis and dysmenorrhea, deep
dyspareunia, and intermenstrual pain constitute its main
symptom complex [1]. CPP is one of the commonest
symptomatology in gynecological outpatient clinics. It
accounts for 10% of office visits to gynecologists, general
clinics, and about a quarter of outpatient consultations in
general gynecological practice and for 40–60% of all
diagnostic laparoscopies [2]. In our department, it varies
from 40–46% of all diagnostic laparoscopy annually. CPP
has a profound impact on a woman’s personal health and
quality of life, including an economic impact through loss
of working hours [1].
Laparoscopy is a valuable tool in the evaluation of
undiagnosed CPP, as it can establish a definite diagnosis
and modify the treatment without resorting to exploratory
laparotomy [3]. In the absence of pathology, there is no
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DOI 10.1007/s10397-010-0612-1established treatment, therefore, treatment is sometimes
unsuccessful, and hysterectomy often becomes the final
resort. Therefore, a conservative surgery, if shown to be
effective, would represent a major improvement in its
management [1]. Recent developments in minimal access
surgery using laparoscopy make ablation of the nerve
plexuses and ganglions in the uterosacral ligaments
(laparoscopic uterosacral nerve ablation (LUNA)) a practi-
cable treatment option [4].
Some recent reports of randomized controlled studies have
clarified some roles of LUNA in the control of pelvic pain [5,
6] ,but systematic review and recent Cochrane reviews [7, 8]
have shown that the currently available research evidence on
LUNA is inconclusive, and therefore, further research is
required among patients in different communities with
different demographic and clinical characteristics to generate
effectiveness evidence in the form of a high-quality,
randomized, controlled trial to assess the principal hypoth-
esis that, in women with chronic pelvic pain in whom
diagnostic laparoscopy reveals either no pathology or mild
endometriosis (American Fertility Society (AFS) score ≤5),
LUNA alleviates pain and improves life quality [4].
Aim of the work
The primary aim of this work is to explore the efficacy and
the safety of LUNA in the relief of pain in women with
CPP in whom diagnostic laparoscopy reveals either no
pathology or mild endometriosis (AFS score ≤5). The
secondary aim was to evaluate the patients' satisfaction
from the procedure during 3, 6, and 12 months follow-up,
and to test the hypothesis that response to LUNA differs
according to type of the pain by two secondary analyses:
(1) women with primary or secondary dysmenorrhea, and
(2) women with deep dyspareunia.
Patients and methods
Thisprospective,randomized,controlledtrialwasconducted
at the endoscopy unit of the Gynecology Department at El
Minia University Hospital, Egypt between the period of June
2004 to December 2008 with single-blind assessment of
outcomes in eligible consenting patients randomized at
diagnostic laparoscopy to LUNA (study group) or to no
pelvic denervation (control group).
Eligibility
All new patients (280 women) who presented to the
Gynecology outpatient clinic with pelvic pain (cyclical or
noncyclical) and/or dyspareunia and who required diagnostic
laparoscopy for evaluation of these conditions were invited to
participate. When they consented to participate, they were
registered prior to randomization (registered patients). Only
190 patients were eligible to randomization into one of the
study groups according to strict inclusions criteria, and the
study protocol was in concordance with the protocol guide-
lines of the LUNATrial Collaboration [3]( F i g .1).
1. Inclusion criteria
Patients with pelvic pain of longer than 6 months in
duration, that was located within the true pelvis or between
and below the anterior iliac crests, associated with functional
disability, did not respond to medical treatment, and planned
diagnostic laparoscopy revealed no pelvic pathology were
considered as eligible patients for the study.
2. Exclusion criteria
Patients with previous LUNA, moderate and severe
endometriosis (AFS score >5), previous surgery for
endometriosis or for pelvic inflammatory disease, previous
hysterectomy, and adnexal pathology were excluded from
the study.
Eligible patients were thoroughly counseled, and in-
formed consent was taken from all the patients. Complete
history was taken, including the patients' present symptoms,
past medical history, medication used, known allergies, and
previous similar attack(s), and method(s) of treatment.
Detailed, general, abdominal, and pelvic examinations were
performed, including a vaginal examination using sterile
speculum. Cervical cytology, pelvic and vaginal ultrasound
was done for all patients. At this point, the women were
randomly assigned to diagnostic laparoscopy to start
therapy according to protocol that has been approved by
the medical ethical committee of the department.
Randomization
Consenting patients (280 patients) were subjected to
diagnostic laparoscopy first, and in the same sitting,
consenting eligible patients (190 patients) were randomized
using computer-generated tables into two equal groups,
including the control group (diagnostic laparoscopy with no
pelvic denervation) and the study group (diagnostic laparos-
copy plus uterosacral nerve ablation).
The patients were allocated to groups using a chance
procedure, blocking, and stratification. Stratified block
randomization was employed to ensure that there was
nearly equal numbers of patients in the two groups within
the prognostic subgroups, even if the study ends prema-
turely so that a chance imbalance in the stratification
variable does not have an effect on the outcome.
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In this study, patients were kept blind to their treatment
allocation until the follow-up in the trial was completed to
avoid the placebo effect that may occur if they know they
have received the active treatment. Unfortunately, single-
blind approach was used, as it was difficult to keep the
surgeon blind to the procedure.
Interventions
Routine preparation was made for a diagnostic laparoscopy
with the patient under general anesthesia. Following
pneumoperitoneum, a laparoscope was used to visualize
the pelvis. Before embarking on operative laparoscopy, an
anatomical pelvic assessment was performed to identify
pelvic structures and pathology. At this stage, patients with
pathology outlined in the exclusion criteria were excluded.
It is expected that around 30% to 50% of women will be
unsuitable for LUNA at operation and were “registered
only” cases. Eligible patients were randomized into one of
the study groups: first group, the control group, laparosco-
py without pelvic denervation, and the second group, the
study group, laparoscopy with uterosacral nerve ablation.
The posterior leaf of the broad ligament was carefully
inspected to identify the course of the ureters, which, on
rare occasions, could be particularly close to the uterosacral
ligaments. Care was also taken to note thin-walled pelvic
veins, which often lie lateral to the uterosacral ligaments. If
accidentallypunctured,theymaycausetroublesomebleeding,
280 patients assessed as candidates for the study 
and consent prior to diagnostic laparoscopy
 90 patients were excluded from the study due to 
* 45 moderate to severe endometeriosis. 
* 18 moderate to severe adhesions  * 11 modterate to sever PID. 
*10 other pelivc pathology  * 6 uterosaceral ligament not accesable. 
190 eligible patients were randomized  
Study group
95 patients have laparoscopy with LUNA
9 patients were excluded did not completed 
the follow up
Control group
95 patients have laparoscopy only 
10 patients were excluded did not completed 
the follow up
Primary pain analysis:
* 25 patients have non cyclical pain
35patients have primary dysmenorrhea * 
* 40 patients have secondary 
dysmenorrhea
30 patients dyspareunia *
Primary pain analysis: 
* 28 patients have non cyclical pain
36 patients have primary dysmenorrhea * 
* 38 patients have secondary 
dysmenorrhea
33 patients have dyspareunia * 
Fig. 1 Flow chart of the study
protocol
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ligaments were identified by manipulation of the uterus in the
right and left lateral planes. Clear identification of the
uterosacral ligaments was a prerequisite for treatment, and
ablation of the ligament was carried out using 5-mm bipolar
electrodiathermy using bipolar Meyerland forceps (the main
unitofthediathermyisadjustedat30W,andenergyisapplied
for 5 s in order to deliver a dose power of coagulation 150 J to
every uterosacral ligament), and then complete transaction of
the uterosacral ligaments was done using a 5-mm curved
scissors supplied with the ability to use monopolar electro-
diathermy if needed. The ablation was started as close to the
posterior aspect of the cervix as possible and continued for a
minimum of 1 cm posterolaterally on either side. The aim of
the procedure was to destroy the sensory nerve fibers and the
secondary ganglia as they leave the uterus and come to lie
within the uterosacral ligaments [3]. Patients with moderate
pelvic adhesion obliterating the douglas pouch or making
access to either uterosacral ligament difficult were excluded
from the study.
Following surgery, the surgeon filled the operation
details on a post-surgery form, including the laparoscopic
finding, technique, the operative time, intraoperative blood
loss, and intraoperative and postoperative complications.
Follow-up protocol and statistical analysis
All patients were followed up after 3, 6, and 12 months
after the ablation. Follow-up visits included: history taking,
clinical examination, and ultrasound (abdominal and vag-
inal) examination. The effectiveness of the procedure was
estimated using a 10-cm visual analog scale (VAS),
anchored at one end as no pain at all, and at the other as
the worst imaginable pain. Also, the VAS ratings were
obtained at 3, 6, and 12 months for each of the types of
pain: noncyclical pain (pain at any other time other than
during periods or during intercourse), primary (spasmodic)
dysmenorrhea, secondary (congestive) dysmenorrhea, and
dyspareunia (pain during intercourse). The success rate was
defined as the percentage of women who reported no,
minimal, or tolerable pain during the period of follow-up
and without hysterectomy or repeated LUNA, and this PAS
was calculated as percentage to simplify the results
(*excellent =10–9, **good =6–8 PAS , ***tolerable =3–
5, ****minimal =0–2 PAS). The patients’ satisfaction was
estimated by asking the patients a direct question (did the
procedure improve your health status?, regarding the need
for additional treatments, resource usage, days off work,
and complications of surgery), and the patients’ answers
determine the degree of satisfaction (if it is excellent [4],
good [3], average [2], or no improvement [1]). Also, the
option if the pain was "worse than before" was evaluated
and was only restricted to complications of the procedure
that worsen the patients' condition. All patients were
followed up for long-term complication and the need for
additional treatment (medical or surgical), which was
considered as treatment failure. Statistical analysis was
performed on an IBM personal computer using SPSS
statistical package for windows (SOSS, Inc, USA). Results
were expressed as mean±SD for quantitative character-
istics, and number and percentage for qualitative character-
istics. Among different groups, statistical comparison was
made using chi-square X2 test or Fisher exact test for
qualitative characteristics and one-way ANOVA for numer-
ical results among different groups. P values of ≤0.05 were
considered as the level of significance.
Findings
There was no statistically significant difference between
both groups regarding demographic and clinical character-
istics of patients (Tables 1 and 2). The efficacy was
comparable between group I and group II at 3, 6, and
12 months of follow-up (P≤0.05). Also, the overall success
rate between group I and group II was comparable to each
other, as it was 77.64%, 76.47%, and 74.11% versus
79.06%, 75.58%, and 73.25% at 3, 6, and 12 months,
respectively(P≤0.05; Table 3). Patients' satisfaction rate did
not vary significantly between group I and group II at 3, 6,
and 12 months follow-up (P≤0.05). The cumulative satisfac-
tion rate was 74.11%, 74.11%, and 71.76% versus 75.58%,
75.58%, and 72.09% at 3, 6, and 12 months between group I
and group II, respectively (P≤0.05; Table 4). In evaluating
the effectiveness of LUNA (when compared to a control or
no treatment) in the treatment of primary (spasmodic)
dysmenorrhea and secondary (congestive) dysmenorrhea,
there was no statistically significant difference between both
groups, (P≤0.05); on the other hand, as regarding the
effectiveness of LUNA in the treatment of dyspareunia, there
was a statistically significant difference between both groups,
(P≥0.05; Fig. 2). There were no statistically significant
difference between group I and group II regarding the
intraoperative and postoperative complications (P≤0.05;
Table 2).
Discussion
Definitive diagnosis of CPP is usually by laparoscopy or
laparotomy. Treatment for CPP depends on the underlying
cause. In some patients, a cause cannot be identified, so
conservative treatments will be tried. If these medical treat-
ments fail, conservative surgical treatment options which
include vaginal uterosacral ligament resection, uterine nerve
ablation, and presacral neurectomy may be beneficial [1–4].
34 Gynecol Surg (2011) 8:31–39Group I (N=85) Group II (N=86) P value
Operative time Range (min) 25–35 30–48 S
(Mean±SD) 27.50±4.51 36.33±7.68
Intraoperative complications (N %)
Bleeding 4/85 (4.70%) 5/86 (5.8%) NS
Visceral injuries 0 0 NS
Vascular injuries 0 0 NS
Conversion to open surgery 0 0 NS
Discharge time Range (days) 1–21 –2N S
(Mean ± SD) 1.33±0.22 1.33±0.22
aPostoperative complications, N (%)
Fever 5/85 (5.88%) 6/86 (6.9%) NS
Postoperative bleeding 0 0 NS
Constipation 0 3 (3.48%) NS
Urinary urgency 0 4 (4.65%) NS
Uterine prolapse 0 2 (2.32%) NS
Painless labor 0 0 NS
Time to return to normal lifestyle Range (days) 4–10 5–10 NS
(Mean ± SD) 6.78±1.55 6.34±1.22
Table 2 Operative and
postoperative data for both
study groups
aIncluding immediate and remote
complications during the period of
follow-up
S significant, NS not significant
Group I (control) N=85 Group II (study) N=86 P value
Age (years) Range 25–45 24–43 NS
(Mean±SD) 31.90±2.44 30.25±2.55
Weight (kg) Range 48–75 50–72 NS
(Mean±SD) 66–11±5.31 67.18±4.34
Height (cm) Range 153–170 152–173 NS
(Mean±SD) 163±1.17 161±2.10
BMI (kg/m
2) Range 24.40–29.55 23.66–28.41 NS
(Mean±SD) 24.80±1.46 25.23±1.25
Parity (N) Range 1–81 –7N S
(Mean±SD) 4.78±1.65 5.43±1.61
Clinical presentation(s), N (%)
Acyclic lower abdominal pain 28 (32.9%) 25 (29%) NS
Congestive dysmenorrhea 38 (44.7%) 40 (46.5%) NS
Spasmodic dysmenorrhea 36 (42.3%) 35 (40.6%) NS
Deep dyspareunia 33 (38.8%) 30 (34.8%) NS
Pervaginal findings, N (%)
Pelvic tenderness 18/85 (21.1%) 19/86 (22.9%) NS
Localized to one fornix 6/18 (33.3%) 7/19 (36.8%) NS
Bilateral 3/18 (16.6%) 3/19 (15.7%) NS
Diffuse 9/18 (50%) 12/19 (63.3%) NS
Fornical fullness 14/85 (16.4%) 12/86 (13.9%) NS
Unilateral 5/14 (35.7%) 5/12 (41.6%) NS
Bilateral 9/14 (64.2%) 7/12 (85.3%) NS
Cul-de-sac nodularity 3/85 (3.5%) 2/86 (2.3) NS
Fixed retroverted uterus 1/85 (1.1%) 1/86 (1.1%) NS
No significant finding 16/85 (18.8%) 18/86 (20.9%) NS
Table 1 Clinical characteristics
of patients in both
study groups
NS not significant
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difference as regards the efficacy and the overall success
rate between group I and group II at 3, 6, and 12 months of
follow-up (P≤0.05). This is in agreement with the results of
other studies, in which LUNA was used to treat patients
with CPP in whom laparoscopy revealed no pathology as
the systematic review (Cochrane) and meta-analysis includ-
ing six randomized, controlled trials (RCTs) [9], reported
that there were no significant differences overall in pain
relief between women treated with LUNA and controls
(women treated with diagnostic laparoscopy or conserva-
tive surgery alone) as pain relief up to 6 months (five
studies, N=258): odds ratio (OR) 1.15, 95% confidence
interval (CI) 0.66 to 1.99, pain relief up to 12 months (four
studies, N=285): OR 1.20, 95% CI 0.72 to 1.99 and pain
relief up to 36 months (one study, N=116): OR 0.84, 95%
CI 0.39 to 1.80). The review states that the effect of
treatment may overlap with the placebo effect of laparos-
copy, reducing differences in short-term efficacy between
groups, and the lack of power to detect a clinically
important difference was an issue of concern in the trials
with null results, and they stated that lack of sustained long-
term benefit could be due to regrowth of nerves or pain
signals being transferred via alternative routes and conse-
quently, because of this last speculation, in the present
study, uterosacral nerve cauterization using bipolar electro-
surgical current and then nerve transaction was used rather
than any procedure alone. In a recent randomized,
controlled trial [10], 80 women were studied with CPP
treated with LUNA or vaginal uterosacral nerve resection
with a follow-up till 12 months, there were no significant
differences between the two study groups with regard to
pain relief. The same results were obtained from recent
meta-analysis [11] used by collecting individual patient
data from the existing trials to provide a comprehensive
assessment of the effectiveness of LUNA that will be
generalizable in various clinical contexts. Also, in the most
recent multicentric, randomized, controlled trial [12] in-
cluding 487 women with CPP lasting longer than 6 months
without or with minimal endometriosis, adhesions, or
pelvic inflammatory disease, recruited to the study by
consultant gynecological surgeons from 18 UK hospitals,
with follow-up conducted by questionnaires mailed at 3 and
6 months and at 1, 2, 3, and 5 years, it concluded that after
a median follow-up of 69 months, there were no significant
differences reported on the visual analog pain scales for the
Table 3 The summation of success rate according to the mean PAS after treatment at 3, 6, 12 month follow-up in both study groups
Group I (N=85) Group II (N=86 ) P value
3MS 6MS 12MS 3MS 6MS 12MS
aNo pain, N (%) 20 (23.52%) 18 (21.17%) 18 (21.17%) 21 (24.41%) 19 (22.09%) 18 (20.93%) NS
bMinimal pain, N (%) 19 (22.35%) 19 (22.35%) 17 (20%) 20 (23.25%) 19 (22.09%) 18 (20.93%) NS
cTolerable pain, N (%) 27 (31.76%) 28 (32.94%) 28 (32.94%) 27 (31.39%) 28 (32.55%) 27 (31.39%) NS
dSevere pain, N (%) 19 (22.35%) 20 (23.52%) 22 (25.88%) 18 (20.93%) 21 (24.41%) 22 (25.58%) NS
Overall success rate (66/85) (77.64%) (65/85) (76.47%) (63/85) 74.11% (68/86) 79.06% (65/86) 75.58 % (63/86) 73.25% NS
NS not significant
aexcellent=10–9
bgood=6–8P A S
ctolerable=3–5
dminimal=0–2P A S
Table 4 Patients' satisfaction rate of the treatment during 3, 6, and 12 months follow-up in both study groups
Group I (N=85) Group II (N=86) P value
3MS 6MS 12MS 3MS 6MS 12MS
Excellent 19/85 (22.35%) 17/85 (20%) 17/85 (20%) 20/86 (23.25%) 19/86 (22.09%) 19/86 (22.09%) NS
Good 26/85 (30.58 %) 24/85 (28.23%) 22/85 (25.88%) 25/86 (29.06%) 23/86 (26.74 %) 22/86 (23.25 %) NS
Moderate 18/85 (21.17%) 22/85 (25.88%) 22/85 (25.88%) 20/86 (23.86 %) 23/86 (26.74%) 21/86 (24.41%) NS
No improvement 22/85 (25.88%) 22/85 (25.88%) 24/85 (28.23%) 21/86 (24.41%) 21/86 (24.41%) 24/86 (27.90%) NS
aCumulative
satisfaction rate
63/85 (74.11%) 63/85 (74.11%) 61/85 (71.76%) 65/86 (75.58%) 65/86 (75.58%) 62/86 (72.09%) NS
aCumulative satisfaction rate = Excellent + Good + Moderate.
Worse than before = restricted only to patients with surgery complications, and it was 0%
36 Gynecol Surg (2011) 8:31–39worst pain between the LUNA group and the no LUNA
group for quality of life.
The cumulative satisfaction rate was 74.11%, 74.11%,
and 71.76% versus 75.58%, 75.58%, and 72.09% at 3, 6,
12 months between group I and group II, respectively (P≤
0.05). This results go hand in hand with the overall
satisfaction rate in the meta-analysis study [9] and other
studies [13, 14], as it stated that there is no significant
difference at the satisfaction rate, or the need of additional
treatment between the study and the control group among
six RCTs they evaluated.
As regarding the effectiveness of LUNA (when compared
to a control or no treatment) in treatment of primary
(spasmodic) dysmenorrhea and secondary (congestive) dys-
menorrhea, there was no statistically significant difference
between both groups, (P≤0.05); on the other hand, as
regarding the effectiveness of LUNA in the treatment of
dyspareunia, there was a statistically significant difference
between both groups, (P≥0.05). The previous results were in
agreement with that of the report of Proctor et al. [9], as in his
systematic review of six RCTs, he reported that, for women
with primary dysmenorrhea, the OR for pain relief at 6 and
12 months was 0.67 (95% CI 0.17 to 2.61) and 0.10 (95% CI
0.03 to 0.03), respectively, in favor of LUNA. For women
with secondary dysmenorrhea, the OR for pain relief at 6 and
12 months was 1.03 (95% CI 0.52 to 2.02) and 0.77 (95% CI
0.43 to 1.39), respectively. In Cochrane Database of
Systematic Reviews [15], regarding the treatment of primary
dysmenorrhea, there was some evidence of the effectiveness
of LUNA when compared to a control or no treatment.
Inthepresentstudy,endometriosiswithanAFSscoreof>5
wasexcludedfromthestudy,asinthemajorityofwomenwho
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Fig. 2 Effect of LUNA at 12 months follow-up in both study groups
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scopic procedure alone or with conservative medical therapy,
as well as with LUNA, it will be difficult to attribute their
response to the LUNA alone or to the adjuvant therapy of
endometriosis, and this is in agreement with the conclusion of
different studies as that of Guyer et al. [13] and Davis et al.
[14]. Also, in a randomized trial of 180 patients with
symptomatic endometriosis, the addition of LUNA to
conservative laparoscopic surgery for endometriosis did not
reduce the medium- or long-term frequency and severity of
recurrent dysmenorrheal [6]. Another randomizedstudyof67
patientswithCPPandlaparoscopicevidenceofendometriosis
found no significant difference in the pain outcome [5].
In the present study, the effectiveness of the LUNA in
relief or improvement of deep dyspareunia was taken with
great interest and discussion because to my knowledge,
there has been few similar reports specifically on the
treatment of primary deep dyspareunia by the LUNA
procedure, as Jung et al. [16] found that of his 12-month
follow-up study of LUNA for treating primary deep
dyspareunia, the satisfactory rates at 3 and 12 months were
66.7% and 50%, respectively, while on the other hand,
Vercellini et al. [6] found no significant advantage on
sexual satisfaction by the LUNA procedure. In a multi-
centric, randomized, controlled trial (JAMA trial) [12], after
a median follow-up of 69 months, there were no significant
differences reported on the visual analog pain scales for the
worst pain (mean difference between the LUNA group and
the no LUNA group, −0.04 cm (95% CI −0.33 to 0.25 cm;
P =0.80), noncyclical pain (−0.11 cm, 95% CI, −0.50 to
0.29 cm]; P =0.60), dysmenorrhea(−0.09cm,95%CI,−0.49
to 0.30 cm; P =0.60), or dyspareunia (0.18 cm, 95%
CI, −0.22 to 0.62 cm; P =0.40), and they concluded that in
women with CPP, LUNA did not result in improvements in
pain, dysmenorrhea, dyspareunia, or quality of life compared
with laparoscopy without pelvic denervation. However, in
our opinion, deep dyspareunia is very complicated in its
pathogenesis, which includes both physical and psychiatric/
psychologic aspects; hence, a verified system comprising of
clarified definitions and criteria in the assessment of
satisfaction or improvement is mandatory, and will be very
difficult to be practiced in our community and with our
patients with the lack of group evaluators, including social
personnel who are qualified for appraising a sexologic and
psychiatric/psychologic questionnaire to give more informed
insight, and so these results need to be evaluated carefully in
a large, randomized trial before it will be generalized.
In the present study, there was no statistically significant
difference between group I and group II regarding intra-
operative and postoperative complications (P≤0.05); only
urge incontinence was significantly observed among
patients with LUNA. All of these complications were
minimal and treated conservatively with no additional
measures. This was in agreement with that of Yuan [1]
who stated that the adverse events of LUNA were less
common. Also, a meta-analysis [9] found that few
complications were reported, while two case reports
described a total of five women with uterine prolapse after
having LUNA; three women were young nulliparous, and
the other two women had a history of vaginal childbirth
[14, 16]. In Cochrane Database of Systematic Reviews [15],
adverse events were significantly more common for
presacral neurectomy; however, the majority had compli-
cations such as constipation, which may spontaneously
improve.
The National Institute for Health and Clinical Excellence
[17] examined LUNA for CPP and will publish guidance
on its safety and efficacy to the NHS in England, Wales,
Scotland, and Northern Ireland. This overview is based on
one Cochrane systematic review and meta-analysis [9–14].
They concluded that there was some evidence for the
effectiveness of LUNA when compared with controls or no
treatment in women with primary dysmenorrhea, and there
were no significant differences in short-term pain relief
between LUNA and LPSN. On the other hand, The
European Society for Human Reproduction and Embryology
published a guideline for the diagnosis and treatment of
endometriosis in 2005 [18]. This guideline states that
“ablation of endometriotic lesions reduces endometriosis-
associated pain and the smallest effect is seen in patients
with minimal disease; there is no evidence that also
performing LUNA is necessary”. A guideline published
by the Royal College of Obstetricians and Gynecologists
states that “There is no evidence that laparoscopic uterine
nerve ablation is necessary when ablating endometriotic
lesions and laparoscopic uterine nerve ablation by itself has
no effect on dysmenorrhea associated with endometriosis”
[19]. So, both uncontrolled or controlled randomized
studies and the present study had proven that LUNA
showed no statistically significant difference in complete
relief of CPP, but it has a role in substantial reduction in
CPP level in well-selected patients, and this may be due the
complicated anatomical and physiological picture of CPP as
anatomically, at least five pathways transmit signals from
noxious stimuli in the pelvis, and these nerve trunks vary in
location and can intersect, with the potential for neuronal
crosstalk so LUNA may obliterate some of the nerve fibers,
but others are interwoven with the pelvic arteries and
ureters [12]. This explanation that LUNA has no role in
reducing CPP was an objective one, not subjective, and if
we generalized this opinion, at the same step, it will be of
no value to ligate the uterine arteries or the internal iliac
arteries to stop severe postpartum hemorrhage, as the uterus
has many other blood sources, but the philosophy of the
LUNA is that it has a short-term effect in complete or
incomplete relief of CPP that will give the patients the
38 Gynecol Surg (2011) 8:31–39chance to return to their normal lifestyle, and then
accommodation and less pain habituation will take place
making their PAS fall to its minimal level, especially when
the patients know that their diagnostic laparoscopy was
free, and these results, if obtained from the LUNA, will be
considered as a relative success event, not an absolute one.
So, after this controversial explanations, LUNA, in well-
selected patients, can be added as an adjuvant last treatment
in patients with CPP when other options of treatment failed,
and laparoscopy was recommended for diagnosis, but it is
not recommended as an indication for LUNA in patients
with CPP.
Conclusion
In conclusion, LUNA can be a last alternative option in well-
selected patients for control of CPP without endometriosis;
however,its effectiveness maynot extendtoother indications.
Also, preliminary experience in the treatment of primary deep
dyspareunia presents a promising perspective on the manage-
ment of deep dyspareunia, especially if it will involve a team
of social, psychological, and gynecological specialists.
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